IL6 and rheumatoid arthritis: For treatment, 51.3% of patients with RA were receiving biologics (mainly anti-TNFα, agents (18.9%) and anti-IL6 agents (14.8%)) compared with 1.9% of patients with SpA (p < 0.001).